MACROGENICS, INC. Restricted Cash and Cash Equivalents
MACROGENICS, INC. (MGNX) had Restricted Cash and Cash Equivalents of $0 as of 2015-12-31, per its 10-K filed 2016-02-29.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2016-02-29
- 2015-12-31: Restricted Cash and Cash Equivalents $0.00.
- 2015-09-30: Restricted Cash and Cash Equivalents $0.00.
- 2015-06-30: Restricted Cash and Cash Equivalents $300.00K.
- 2015-03-31: Restricted Cash and Cash Equivalents $300.00K.
| Period end | Restricted Cash and Cash Equivalents | Restricted Cash and Cash Equivalents as first filed |
|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-29 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $300.00K 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $300.00K 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $300.00K 10-K · filed 2016-02-29 | |
| 2014-09-30 | $300.00K 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $405.00K 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $404.85K 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $405.00K 10-K · filed 2015-03-03 | $404.85K 10-K · filed 2014-03-20 |
| 2013-09-30 | $404.85K 10-Q · filed 2013-11-12 | |
| 2012-12-31 | $404.85K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |